| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 2.16 | 50.6% |
| Total Income | 2.16 | 50.6% |
| Expenditure | 16.52 | 15.5% |
| PBT | -65.54 | 700.2% |
| Net Profit | -65.54 | 700.2% |
| OPM | — | |
| NPM | — | |
| EPS | -0.75 | 212.5% |
Opus Genetics Announces Q1 2026 Financial Results and Corporate Update
12 May 2026 · 12 May, 4:36 pm
Summary
Opus Genetics announced its financial results for the first quarter ended March 31, 2026. The company's license and collaborations revenue was $2.2 million, compared to $4.4 million for the same period in 2025. Research and Development expenses increased to $10.6 million, while General and Administrative expenses decreased to $5.9 million. The net loss for the quarter was $65.5 million, compared to a net loss of $8.2 million for the same period in 2025. As of March 31, 2026, Opus Genetics had cash and cash equivalents of $60 million and believes its aggregate cash resources will fund operations into 2029.
Key Highlights
- 1
Opus Genetics reported license and collaborations revenue of $2.2 million for the quarter ended March 31, 2026, compared to $4.4 million for the same period in 2025.
- 2
Research and Development expenses increased to $10.6 million for the quarter ended March 31, 2026, from $8.0 million in the same period in 2025.
- 3
General and Administrative expenses decreased to $5.9 million for the quarter ended March 31, 2026, compared to $6.3 million for the same period in 2025.
- 4
Net loss for the quarter ended March 31, 2026, was $65.5 million, or ($0.75) per basic and diluted share, compared to a net loss of $8.2 million, or ($0.24) per basic and diluted share, for the same period in 2025.
- 5
As of March 31, 2026, Opus Genetics had cash and cash equivalents of $60 million.
- 6
The company expects to announce three-month topline data from Cohort 1 of the Phase 1/2 trial in September 2026.
- 7
The OPGx-RDH12 program is expected to enter the clinic in the fourth quarter of 2026.
Management Comments
George Magrath
M.D.
With encouraging momentum across both our LCA5 and BEST1 gene therapy programs, Opus Genetics is entering a defining stretch where we believe our precision targeted approach can reshape what’s possible for patients with inherited retinal diseases. Our upcoming BEST1 Cohort 1 clinical data and June R&D Science Forum will provide key opportunities to showcase the depth and maturity of our science and pipeline. Backed by a strong balance sheet and disciplined capital strategy, we are well-positioned to advance our lead programs toward pivotal trials, and accelerate our earlier‑stage RDH12, MERTK, and RHO programs into the clinic.
Informational and educational content only. Not investment advice.